Page last updated: 2024-12-05

2-aminobenzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Aminobenzimidazole is a heterocyclic aromatic compound with a wide range of applications in various fields. It is synthesized through various methods, including the condensation of o-phenylenediamine with formic acid. 2-Aminobenzimidazole possesses significant biological activity, including antibacterial, antifungal, and anti-inflammatory properties. These activities make it a subject of intense research for developing new drugs and therapeutic agents. Moreover, it serves as a key precursor for the synthesis of various pharmaceuticals, dyes, and polymers. The unique structural features of 2-Aminobenzimidazole, such as its electron-rich aromatic system, make it a versatile building block for organic synthesis and drug development. Researchers are constantly exploring its potential in various applications, including medicinal chemistry, material science, and catalysis.'

2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13624
CHEMBL ID305513
CHEBI ID27822
SCHEMBL ID9098
SCHEMBL ID3350089
SCHEMBL ID2475507
MeSH IDM0089080

Synonyms (98)

Synonym
EU-0067838
AC-15858
BIDD:GT0837
aminobenzimidazole
usaf ek-4037
1h-benzimidazol-2-amine
benzimidazole, 2-amino-
nsc7628
2-iminobenzimidazoline
nsc-7628
wln: t56 bm dnj cz
nsc-27793
nsc27793
chembl305513 ,
imidazole c-2 deriv. 3
jmc524454 compound 5
1h-1,3-benzodiazol-2-amine
bdbm7960
OPREA1_243328
NCGC00091178-01
nsc 7628
2-amino benzimidazole
caswell no. 033aa
brn 0116525
einecs 213-280-6
ai3-60094
ccris 4354
nsc 27793
934-32-7
2-aminobenzimidazole
inchi=1/c7h7n3/c8-7-9-5-3-1-2-4-6(5)10-7/h1-4h,(h3,8,9,10
2FPZ
2FX6
2-aminobenzimidazole, 97%
CHEBI:27822 ,
benzimidazol-2-ylamine
MLS001074865
smr000019082
A0850
AKOS000104081
ax7 ,
HMS1741L08
1h-benzoimidazol-2-ylamine
HMS2865C12
NCGC00091178-02
e65de7521v ,
5-25-10-00372 (beilstein handbook reference)
unii-e65de7521v
NCGC00257027-01
dtxcid004465
cas-934-32-7
tox21_303120
dtxsid1024465 ,
NCGC00259498-01
tox21_201949
AM804572
2-benzimidazolamine
STL283126
FT-0611230
1h-benzimidazol-2-ylamine
AQ-738/40188880
1h-benzo[d]imidazol-2-amine
aminobenzimidazole, 2-
BBL033933
1h-benz[d]imidazole-2-amine
2-ammobenzimidazole
2-aminobenzoimidazole
benzimidazole amine
2-amino-benzimidazole
benzimidazole-amine
2-amino-1h-benzimidazole
1,3-dihydro-benzoimidazol-2-ylidene amine
1h-benzoimidazol-2-amine
SCHEMBL9098
SCHEMBL3350089
SCHEMBL2475507
STR00452
TS-01718
Q-101103
162938-41-2
mfcd00005596
F0266-1828
2-aminobenzimidazole, pestanal(r), analytical standard
CS-D1373
2-aminobenzimidazol
Z104378302
SY032901
2-ab (2-amine-1h-benzimidazole)
carbendazim metabolite
Q27103356
YSWG454
2h-benzimidazol-2-imine,1,3-dihydro-(9ci)
EN300-18977
1h-1,3-benzimidazol-2-amine
W10172
2-iminobenzimidazoline sriramchem-aminobenzimidazole
SRCA-00001
SB75578

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Thus, 2-aminobenzimidazoles may have improved pharmacokinetic properties which could increase the bioavailability of inhibitors which contain this moiety."( Identification of novel inhibitors of urokinase via NMR-based screening.
Boyd, S; Davidson, D; Fesik, SW; Hajduk, PJ; Nettesheim, D; Nienaber, V; Rockway, T; Severin, J; Smith, R, 2000
)
0.76
" These efforts led to the discovery of 16, a highly potent, selective, and orally bioavailable inhibitor of IRAK-4."( Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.
Cao, Z; Gao, X; Jaen, JC; Johnstone, S; Liu, J; Lively, S; Miao, S; Powers, JP; Sudom, A; Sun, D; Tomooka, C; Walker, NP; Wang, Z; Wright, M; Yan, X; Ye, Q, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
marine xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency44.89490.002541.796015,848.9004AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.67913.189029.884159.4836AID1224846
USP1 protein, partialHomo sapiens (human)Potency0.17780.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency6.51310.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency9.01730.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency28.18380.000221.22318,912.5098AID588515
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency37.02210.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency19.00930.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency29.91740.000417.946075.1148AID1346784
retinoid X nuclear receptor alphaHomo sapiens (human)Potency31.62280.000817.505159.3239AID588544
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.32840.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency11.22020.001024.504861.6448AID588535
aryl hydrocarbon receptorHomo sapiens (human)Potency38.56860.000723.06741,258.9301AID743085; AID743122
activating transcription factor 6Homo sapiens (human)Potency26.60530.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency46.472519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency46.10190.057821.109761.2679AID1159526
eyes absent homolog 2 isoform aHomo sapiens (human)Potency19.95261.199814.641950.1187AID488837
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Tryptase beta-2Homo sapiens (human)Ki155.0000110.0000155.0000200.0000AID977610
Chain A, Tryptase beta-2Homo sapiens (human)Ki155.0000110.0000155.0000200.0000AID977610
Chain A, Tryptase beta-2Homo sapiens (human)Ki155.0000110.0000155.0000200.0000AID977610
Chain A, TrypsinBos taurus (cattle)Ki155.0000110.0000155.0000200.0000AID977610
Chain A, Tryptase beta-2Homo sapiens (human)Ki155.0000110.0000155.0000200.0000AID977610
Membrane primary amine oxidase Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00600.50301.0000AID753428
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)200.00000.03703.385910.0000AID215985
Cationic trypsinBos taurus (cattle)Ki155.00000.00001.07539.0000AID1797191
Tryptase beta-2Homo sapiens (human)Ki155.00000.00101.05323.7000AID1797191
Transcriptional activator protein LasRPseudomonas aeruginosa PAO1IC50 (µMol)134.16670.11003.15839.0000AID1855545; AID1855546; AID1855564
7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)IC50 (µMol)44.00000.05201.20935.6000AID1596624
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)Ki1,800.00000.26202.93587.0000AID1796109
Membrane primary amine oxidaseHomo sapiens (human)IC50 (µMol)4.10000.02001.04004.1000AID753430
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)Kd18.00000.03900.03900.0390AID1596626
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
proteolysisTryptase beta-2Homo sapiens (human)
purine nucleoside catabolic process7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA repair7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to oxidative stress7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
male gonad development7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA protection7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to cadmium ion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
inflammatory responseMembrane primary amine oxidaseHomo sapiens (human)
cell adhesionMembrane primary amine oxidaseHomo sapiens (human)
amine metabolic processMembrane primary amine oxidaseHomo sapiens (human)
response to antibioticMembrane primary amine oxidaseHomo sapiens (human)
negative regulation of primary amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityTryptase beta-2Homo sapiens (human)
protein bindingTryptase beta-2Homo sapiens (human)
serine-type peptidase activityTryptase beta-2Homo sapiens (human)
5'-(N(7)-methylguanosine 5'-triphospho)-[mRNA] hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
protein binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
dATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
snoRNA binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
metal ion binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
ATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-dATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
N6-methyl-(d)ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
O6-methyl-dGTP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
copper ion bindingMembrane primary amine oxidaseHomo sapiens (human)
calcium ion bindingMembrane primary amine oxidaseHomo sapiens (human)
protein bindingMembrane primary amine oxidaseHomo sapiens (human)
primary amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
identical protein bindingMembrane primary amine oxidaseHomo sapiens (human)
protein heterodimerization activityMembrane primary amine oxidaseHomo sapiens (human)
quinone bindingMembrane primary amine oxidaseHomo sapiens (human)
aliphatic amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
collagen-containing extracellular matrixTryptase beta-2Homo sapiens (human)
extracellular spaceTryptase beta-2Homo sapiens (human)
acrosomal vesicle7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
extracellular space7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nucleus7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrial matrix7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytosol7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nuclear membrane7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
cytoplasmMembrane primary amine oxidaseHomo sapiens (human)
plasma membraneMembrane primary amine oxidaseHomo sapiens (human)
microvillusMembrane primary amine oxidaseHomo sapiens (human)
cell surfaceMembrane primary amine oxidaseHomo sapiens (human)
membraneMembrane primary amine oxidaseHomo sapiens (human)
early endosomeMembrane primary amine oxidaseHomo sapiens (human)
endoplasmic reticulumMembrane primary amine oxidaseHomo sapiens (human)
Golgi apparatusMembrane primary amine oxidaseHomo sapiens (human)
early endosomeMembrane primary amine oxidaseHomo sapiens (human)
plasma membraneMembrane primary amine oxidaseHomo sapiens (human)
endoplasmic reticulumMembrane primary amine oxidaseHomo sapiens (human)
Golgi apparatusMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1596626Binding affinity to recombinant His-tagged MTH1 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as dissociation constant by isothermal titration calorimetry2019European journal of medicinal chemistry, Aug-01, Volume: 175Ligand retargeting by binding site analogy.
AID1741933Antiproliferative activity against human HeLa cells assessed as growth inhibition at 20 uM viability after 72 hrs by SRB assay relative to control2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of 2-(2-aminobenzo[d]thiazol-6-yl) benzo[d]oxazol-5-amine derivatives that regulated HPV relevant cellular pathway and prevented cervical cancer from abnormal proliferation.
AID753428Inhibition of rat VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
AID67529The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID213433Acid dissociation constant (pKa) of the compound2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Identification of novel inhibitors of urokinase via NMR-based screening.
AID1855545Inhibition of Pseudomonas aeruginosa PAO-JP2 LasR co-transfected with LVAgfp reporter assessed as inhibition of GFP production by fluorescence based analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation.
AID1179809Dissociation constant, pKa of the compound2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site.
AID773510Inhibition of Trypanosoma brucei PTR1 by spectrophotometry2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Drug discovery for neglected diseases: molecular target-based and phenotypic approaches.
AID1175065Binding affinity to HIV-1 TAR RNA by Tat-TAR fluorimetric competition assay2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR.
AID1855546Inhibition of Pseudomonas aeruginosa PAO-JG21 LasR co-transfected with LVAgfp reporter assessed as inhibition of GFP production by fluorescence based analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation.
AID1855564Inhibition of Pseudomonas aeruginosa PAO1 LasR2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation.
AID753430Inhibition of human VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
AID210973Percentage viability reduction of Trichinella spiralis muscle larvae after 3 days of incubation2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID397258Apparent inhibition of Trypanosoma brucei pteridine reductase 1-mediated reduction of cytochrome c2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.
AID75268The compound was tested in vitro against the protozoa Giardia lamblia, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID1596624Inhibition of recombinant His-tagged MTH1 (unknown origin) expressed in Escherichia coli BL21(DE3) cells using dGTP as substrate incubated for 15 mins by malachite green dye based pyrophosphatase coupled colorimetric assay2019European journal of medicinal chemistry, Aug-01, Volume: 175Ligand retargeting by binding site analogy.
AID1855565Inhibition of Pseudomonas aeruginosa PAO1 RhlR2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation.
AID397261Inhibition of Trypanosoma brucei DHFR-mediated reduction of cytochrome c at upto 500 uM2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.
AID1339468Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to contr2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID1339469Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID215985Inhibitory activity against Urokinase-type plasminogen activator2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Identification of novel inhibitors of urokinase via NMR-based screening.
AID397263Inhibition of human DHFR-mediated reduction of cytochrome c at upto 500 uM2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.
AID1596625Binding affinity to recombinant His-tagged MTH1 (unknown origin) expressed in Escherichia coli BL21(DE3) cells by isothermal titration calorimetry2019European journal of medicinal chemistry, Aug-01, Volume: 175Ligand retargeting by binding site analogy.
AID284279Antiamnesic activity against Entamoeba histolytica2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Molecular modeling of some 1H-benzimidazole derivatives with biological activity against Entamoeba histolytica: a comparative molecular field analysis study.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Biochemistry, May-16, Volume: 45, Issue:19
Structure-guided design of peptide-based tryptase inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2006Biochemistry, May-16, Volume: 45, Issue:19
Structure-guided design of peptide-based tryptase inhibitors.
AID1796109QC Inhibition Testing from Article 10.1074/jbc.M309077200: \\Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators.\\2003The Journal of biological chemistry, Dec-12, Volume: 278, Issue:50
Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators.
AID1799172PTR1 Activity Assay from Article 10.1021/jm900414x: \\One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.\\2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.
AID1797191Enzyme Assay and Determination of the Inhibition Constants from Article 10.1021/bi060173m: \\Structure-guided design of peptide-based tryptase inhibitors.\\2006Biochemistry, May-16, Volume: 45, Issue:19
Structure-guided design of peptide-based tryptase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (3.03)18.7374
1990's2 (2.02)18.2507
2000's26 (26.26)29.6817
2010's54 (54.55)24.3611
2020's14 (14.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.31 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index52.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other98 (98.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]